Meeting of the Pain Management Best Practices Inter-Agency Task Force, 19565-19566 [2018-09379]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 86 / Thursday, May 3, 2018 / Notices
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the guidance to the Division of
Drug Information, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002; or to the Office of
Communication, Outreach and
Development, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128,
Silver Spring, MD 20993–0002. Send
VerDate Sep<11>2014
17:29 May 02, 2018
Jkt 244001
one self-addressed adhesive label to
assist the office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the guidance document.
FOR FURTHER INFORMATION CONTACT:
Peter Chen, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10001 New Hampshire
Ave., Hillandale Building, Rm. 2112,
Silver Spring, MD 20993, 240–402–
8605, Peter.Chen@fda.hhs.gov; or
Stephen Ripley, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave, Bldg. 71, Rm. 7301,
Silver Spring, MD 20993–0002, 240–
402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a guidance for industry entitled
‘‘Assessing User Fees Under the
Prescription Drug User Fee
Amendments of 2017.’’ This guidance
concerns the implementation of the
PDUFA VI and certain changes in
policies and procedures surrounding its
application. Because PDUFA VI created
significant changes to the user fee
program, this guidance serves to provide
an explanation about the new fee
structure and types of fees for which
applicants are responsible.
PDUFA VI provides two different fee
types that applicants pay: Application
and program fees. This guidance
describes when these fees are incurred
and the process by which applicants can
submit payments. The guidance also
provides information on consequences
of failing to pay PDUFA VI fees as well
as the process for submitting a
reconsideration and appeals request.
In the Federal Register of October 13,
2017 (82 FR 47748), FDA announced the
availability of a draft version of this
guidance and provided interested
parties an opportunity to submit
comments. We have reviewed the
comments submitted to the docket and
determined that they did not raise any
relevant issues. This guidance does not
include any substantive changes from
the draft guidance.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on assessing user fees
under PDUFA VI. It does not establish
any rights for any person and is not
binding on FDA or the public. You can
use an alternative approach if it satisfies
the requirements of the applicable
statutes and regulations. This guidance
is not subject to Executive Order 12866.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
19565
II. Electronic Access
Persons with access to the internet
may obtain the guidance at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm, or
https://www.regulations.gov.
Dated: April 24, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–09366 Filed 5–2–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Pain Management Best
Practices Inter-Agency Task Force
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting is scheduled to be held
for the Pain Management Best Practices
Inter-Agency Task Force (Task Force).
The meeting will be open to the public;
public comment sessions will be held
during the meeting.
DATES: The inaugural meeting will be
held on Wednesday, May 30, 2018, from
9:30 a.m. to 5:00 p.m. Eastern Time and
Thursday, May 31, 2018, from 9:00 a.m.
to 3:30 p.m. Eastern Time The agenda
will be posted on the Task Force
website at https://www.hhs.gov/ash/
advisory-committees/pain/.
ADDRESSES: U.S. Department of Health
and Human Services, Hubert H.
Humphrey Building, Great Hall, 200
Independence Avenue SW, Washington,
DC 20201.
FOR FURTHER INFORMATION CONTACT:
Alicia Richmond Scott, Designated
Federal Officer, Pain Management Best
Practices Inter-Agency Task Force, U.S.
Department of Health and Human
Services, Office of the Assistant
Secretary for Health, 200 Independence
Avenue SW, Room 736E, Washington,
DC 20201. Email: paintaskforce@
hhs.gov.
SUMMARY:
Section
101 of the Comprehensive Addiction
and Recovery Act of 2016 (CARA)
authorizes the Secretary of Health and
Human Services, in cooperation with
SUPPLEMENTARY INFORMATION:
E:\FR\FM\03MYN1.SGM
03MYN1
sradovich on DSK3GMQ082PROD with NOTICES
19566
Federal Register / Vol. 83, No. 86 / Thursday, May 3, 2018 / Notices
the Secretaries of Defense and Veterans
Affairs, to convene the Task Force no
later than two years after the date of the
enactment of CARA (by July 22, 2018)
and develop a report to Congress with
updates on best practices and
recommendations on addressing gaps or
inconsistencies for pain management,
including chronic and acute pain. The
Task Force is governed by the
provisions of the Federal Advisory
Committee Act (FACA), Public Law 92–
463, as amended (5 U.S.C. App), which
sets forth standards for the formation
and use of advisory committees.
The Task Force will identify, review,
and determine whether there are gaps or
inconsistencies between best practices
for pain management, including chronic
and acute pain, developed or adopted
by federal agencies; propose updates to
best practices and recommendations on
addressing identified gaps or
inconsistencies; provide the public with
an opportunity to comment on any
proposed updates and
recommendations; and develop a
strategy for disseminating such
proposed updates and recommendations
to relevant federal agencies and the
general public.
This inaugural meeting of the Task
Force will consist of an overview of
various topics surrounding pain
management, and the establishment of
the Task Force subcommittee structure.
Federal, state, local, and professional
medical and health organization
representatives will provide their
current perspectives on pain
management. The Task Force will
discuss clinical best practices, gaps and
inconsistencies focused on prevention
and treatment; mental health and
addiction; special populations;
education; providers; payors; service
and delivery; and research and
innovation. Personal testimonials of
people living in pain will be given. The
Task Force will deliberate and vote on
establishing subcommittees for
developing the report to Congress.
Information about the final meeting
agenda will be posted prior to the
meeting on the Task Force website:
https://www.hhs.gov/ash/advisorycommittees/pain/.
Members of the public are invited to
participate in person or by webcast. To
join the meeting, individuals must preregister at the Task Force website at
https://www.hhs.gov/ash/advisorycommittees/pain/. Seating
will be provided first to those who have
pre-registered. Anyone who has not preregistered will be accommodated on a
first come, first served basis if
additional seats are available 10 minutes
before the meeting starts. Individuals
VerDate Sep<11>2014
17:29 May 02, 2018
Jkt 244001
who need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
indicate the special accommodation
when registering online or by notifying
the Office of the Assistant Secretary for
Health via email at paintaskforce@
hhs.gov by May 22, 2018. The subject
line of the email should read, ‘‘Task
Force Meeting Accommodations.’’ NonU.S. citizens who plan to attend in
person are required to provide
additional information and must notify
the Task Force staff via email at
paintaskforce@hhs.gov 10 business days
before the meeting, May 16, 2018. For
those unable to attend in person, a live
webcast will be available. More
information on registration and
accessing the webcast can be found at
https://www.hhs.gov/ash/advisorycommittees/pain/.
Members of the public can provide
comments at the Task Force meeting
during the following designated dates
and times: May 30, 2018 from 11:40 a.m.
to 12:10 p.m. Eastern Time and May 31,
2018 from 1:50 p.m. to 2:20 p.m. Eastern
Time. Public comments made during
the meeting will be limited to three
minutes per person to ensure time is
allotted for all those wishing to speak.
Individuals are also welcome to submit
their written comments. Written
comments should not exceed three
pages in length. Individuals submitting
written comments should submit their
comments through the Federal
eRulemaking Portal at https://
www.regulations.gov by May 25, 2018.
Dated: April 26, 2018.
Vanila M. Singh,
Chief Medical Officer, Office of the Assistant
Secretary for Health.
[FR Doc. 2018–09379 Filed 5–2–18; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Stakeholder Listening Session in
Preparation for the 71st World Health
Assembly; Meeting
Subject: Office of Global Affairs:
Stakeholder Listening Session in
preparation for the 71st World Health
Assembly
Time and date: Friday, May 11th,
2018, 3:00 p.m.–4:30 p.m. EST
Place: Hubert H. Humphrey Building,
Auditorium, 200 Independence Ave,
SW, Washington, District of Columbia
20201.
Status: Open, but requiring RSVP to
OGA.RSVP@hhs.gov by Monday, May 7,
2018.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Purpose: The U.S. Department of
Health and Human Services (HHS)—
charged with leading the U.S. delegation
to the 71st World Health Assembly—
will hold an informal Stakeholder
Listening Session on Friday, May 11
from 3:00 p.m. to 4:30 p.m., in the
Hubert H. Humphrey Building
Auditorium, 200 Independence Ave.
SW, Washington, DC 20201.
The Stakeholder Listening Session
will help the HHS Office of Global
Affairs prepare the U.S. delegation for
the World Health Assembly by taking
full advantage of the knowledge, ideas,
feedback, and suggestions from all
individuals interested in and affected by
agenda items to be discussed at the 71st
World Health Assembly. Participants
will be limited to 3 minute statements
per agenda item. Your input will
contribute to informing U.S. positions as
we negotiate with our international
colleagues at the World Health
Assembly on these important health
topics.
The listening session will be
organized by agenda item, and
participation is welcome from all
individuals, including individuals
familiar with the following topics and
groups:
• Public health and advocacy
activities;
• State, local, and Tribal issues;
• Private industry;
• Minority health organizations; and
• Academic and scientific
organizations.
All agenda items to be discussed at
the 71st World Health Assembly can be
found at this website: https://
apps.who.int/gb/ebwha/pdf_files/
WHA71/A71_1-en.pdf
RSVP: Due to security restrictions for
entry into the HHS Hubert H. Humphrey
Building, RSVPs are required for this
event. Please send your full name and
organization to OGA.RSVP@hhs.gov .
Please RSVP no later than Monday, May
7, 2018.
If you are not a U.S. citizen and do
not have a U.S. government issued form
of identification, please note this in the
subject line of your RSVP, and our office
will contact you to gain additional
biographical information required for
your clearance. Photo identification for
all attendees is required for building
access without exception.
Written comments are welcome and
encouraged, even if you are planning on
attending in person. Please send your
written comments to OGA.RSVP@
hhs.gov.
We look forward to hearing your
comments related to the 71st World
Health Assembly agenda items.
E:\FR\FM\03MYN1.SGM
03MYN1
]]>Agencies
[Federal Register Volume 83, Number 86 (Thursday, May 3, 2018)]
[Notices]
[Pages 19565-19566]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09379]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Pain Management Best Practices Inter-Agency Task
Force
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) is hereby giving notice
that a meeting is scheduled to be held for the Pain Management Best
Practices Inter-Agency Task Force (Task Force). The meeting will be
open to the public; public comment sessions will be held during the
meeting.
DATES: The inaugural meeting will be held on Wednesday, May 30, 2018,
from 9:30 a.m. to 5:00 p.m. Eastern Time and Thursday, May 31, 2018,
from 9:00 a.m. to 3:30 p.m. Eastern Time The agenda will be posted on
the Task Force website at https://www.hhs.gov/ash/advisory-committees/pain/.
ADDRESSES: U.S. Department of Health and Human Services, Hubert H.
Humphrey Building, Great Hall, 200 Independence Avenue SW, Washington,
DC 20201.
FOR FURTHER INFORMATION CONTACT: Alicia Richmond Scott, Designated
Federal Officer, Pain Management Best Practices Inter-Agency Task
Force, U.S. Department of Health and Human Services, Office of the
Assistant Secretary for Health, 200 Independence Avenue SW, Room 736E,
Washington, DC 20201. Email: [email protected].
SUPPLEMENTARY INFORMATION: Section 101 of the Comprehensive Addiction
and Recovery Act of 2016 (CARA) authorizes the Secretary of Health and
Human Services, in cooperation with
[[Page 19566]]
the Secretaries of Defense and Veterans Affairs, to convene the Task
Force no later than two years after the date of the enactment of CARA
(by July 22, 2018) and develop a report to Congress with updates on
best practices and recommendations on addressing gaps or
inconsistencies for pain management, including chronic and acute pain.
The Task Force is governed by the provisions of the Federal Advisory
Committee Act (FACA), Public Law 92-463, as amended (5 U.S.C. App),
which sets forth standards for the formation and use of advisory
committees.
The Task Force will identify, review, and determine whether there
are gaps or inconsistencies between best practices for pain management,
including chronic and acute pain, developed or adopted by federal
agencies; propose updates to best practices and recommendations on
addressing identified gaps or inconsistencies; provide the public with
an opportunity to comment on any proposed updates and recommendations;
and develop a strategy for disseminating such proposed updates and
recommendations to relevant federal agencies and the general public.
This inaugural meeting of the Task Force will consist of an
overview of various topics surrounding pain management, and the
establishment of the Task Force subcommittee structure. Federal, state,
local, and professional medical and health organization representatives
will provide their current perspectives on pain management. The Task
Force will discuss clinical best practices, gaps and inconsistencies
focused on prevention and treatment; mental health and addiction;
special populations; education; providers; payors; service and
delivery; and research and innovation. Personal testimonials of people
living in pain will be given. The Task Force will deliberate and vote
on establishing subcommittees for developing the report to Congress.
Information about the final meeting agenda will be posted prior to the
meeting on the Task Force website: https://www.hhs.gov/ash/advisory-committees/pain/.
Members of the public are invited to participate in person or by
webcast. To join the meeting, individuals must pre-register at the Task
Force website at https://www.hhs.gov/ash/advisory-committees/pain/. Seating will be provided first to those who have pre-
registered. Anyone who has not pre-registered will be accommodated on a
first come, first served basis if additional seats are available 10
minutes before the meeting starts. Individuals who need special
assistance, such as sign language interpretation or other reasonable
accommodations, should indicate the special accommodation when
registering online or by notifying the Office of the Assistant
Secretary for Health via email at [email protected] by May 22,
2018. The subject line of the email should read, ``Task Force Meeting
Accommodations.'' Non-U.S. citizens who plan to attend in person are
required to provide additional information and must notify the Task
Force staff via email at [email protected] 10 business days before
the meeting, May 16, 2018. For those unable to attend in person, a live
webcast will be available. More information on registration and
accessing the webcast can be found at https://www.hhs.gov/ash/advisory-committees/pain/.
Members of the public can provide comments at the Task Force
meeting during the following designated dates and times: May 30, 2018
from 11:40 a.m. to 12:10 p.m. Eastern Time and May 31, 2018 from 1:50
p.m. to 2:20 p.m. Eastern Time. Public comments made during the meeting
will be limited to three minutes per person to ensure time is allotted
for all those wishing to speak. Individuals are also welcome to submit
their written comments. Written comments should not exceed three pages
in length. Individuals submitting written comments should submit their
comments through the Federal eRulemaking Portal at https://www.regulations.gov by May 25, 2018.
Dated: April 26, 2018.
Vanila M. Singh,
Chief Medical Officer, Office of the Assistant Secretary for Health.
[FR Doc. 2018-09379 Filed 5-2-18; 8:45 am]
BILLING CODE 4150-28-P
